A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of Metadoxine (MG01CI) 1400 mg, Administered as Repeated Doses to Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 13 Jan 2014
At a glance
- Drugs Metadoxine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Pharmacokinetics
- Sponsors Alcobra
- 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 10 Sep 2013 New trial record